logo

HOME > RESEARCH > Senolytic Drugs Improve Memory and Reduce Brain Cholesterol During Aging

Senolytic Drugs Improve Memory and Reduce Brain Cholesterol During Aging

13.png


The brain contains roughly one-quarter of the body’s cholesterol despite accounting for only about 2% of body weight. Most brain cholesterol must also be produced locally because circulating cholesterol cannot readily cross the blood-brain barrier. This tightly regulated lipid supply supports neuronal membranes and communication, but cholesterol metabolism can become disrupted with age.


Astrocytes play a major role in maintaining this balance. These support cells produce and distribute cholesterol throughout the brain, while aging can cause astrocytes to accumulate excess lipids and enter cellular senescence. Senescent cells stop dividing but remain metabolically active, releasing inflammatory molecules that can damage surrounding tissue.


Researchers have increasingly investigated senolytic drugs, which selectively eliminate senescent cells, as a way to counter this process. A new study published in the journal Mechanisms of Ageing and Development examined the combination of dasatinib and quercetin and found that treatment improved memory in mice while suppressing cholesterol production in astrocytes. The findings connect two features of brain aging that researchers often study separately: cellular senescence and disrupted lipid metabolism.


Dasatinib and Quercetin Improved Memory

Researchers used young male mice exposed to D-galactose for eight weeks to induce features associated with accelerated aging, including oxidative stress (the buildup of harmful, reactive molecules in cells), inflammation, mitochondrial dysfunction, and cellular senescence (a dysfunctional state where cells can emit inflammatory molecules). Two weeks after starting D-galactose, one group began receiving daily oral doses of dasatinib at 5 mg/kg and quercetin at 50 mg/kg for six weeks.


Dasatinib is a prescription cancer drug, while quercetin is a plant-derived compound commonly sold as a dietary supplement. Together, D+Q represents one of the most widely studied senolytic combinations.


The treatment reduced signs of cellular senescence in the hippocampus, a brain region essential for learning and memory. Levels of the senescence-associated proteins p16 and p21 also declined.


The researchers then tested whether these biological changes translated into better cognitive function. D+Q-treated mice performed significantly better in a test of spatial working memory, the ability to temporarily remember and use information about their surroundings, and a novel object recognition test that measures recognition memory, the ability to distinguish something previously encountered from something new. Differences in movement and exploratory behavior did not explain the improvement, strengthening the evidence that treatment affected memory itself. 


Senolytics Changed Cholesterol Metabolism in the Brain

The researchers analyzed thousands of proteins and lipids in the hippocampus to determine what might explain the cognitive improvement. Their analysis pointed strongly toward cholesterol metabolism.


D-galactose exposure increased several types of lipids in the hippocampus, including ceramides and phospholipids. D+Q reversed much of this accumulation. The treatment also reduced several proteins involved in cholesterol production, indicating that senolytics were suppressing the brain’s cholesterol biosynthesis pathway.


Total hippocampal cholesterol declined after treatment. Levels of malondialdehyde, a marker of lipid peroxidation and oxidative damage, also fell. These changes matter because excess or poorly regulated lipids can increase oxidative stress and interfere with cellular function in the aging brain.


Brain Lipid Metabolism Could Become a Target for Cognitive Aging

Cellular senescence has attracted attention as a potential driver of age-related disease because senescent cells accumulate in many tissues and can promote chronic inflammation. The new findings suggest that the metabolic state of these cells may be equally important for understanding how they damage the aging brain.


Astrocytes occupy a particularly important position in this process because neurons depend on them for metabolic and lipid support. Excess cholesterol production and lipid storage could therefore connect astrocyte senescence with oxidative stress, inflammation, and impaired neuronal function. Targeting this metabolic dysfunction may eventually provide another route for protecting cognition.


The study does not establish D+Q as a treatment for cognitive aging. Researchers used young male mice subjected to chemically accelerated aging rather than naturally aged animals, and the authors note that studies in naturally aged and neurodegenerative models are still needed. Dasatinib and quercetin also have biological effects unrelated to senescent-cell clearance, making it difficult to determine how much of the cholesterol response came specifically from their senolytic activity.


The more significant finding may be the connection between two established features of brain aging. Cellular senescence can alter the metabolism of the cells that accumulate with age, while disrupted lipid handling can reinforce inflammation and cellular dysfunction. The ability to interrupt that cycle in astrocytes identifies cholesterol regulation as a potential component of future strategies designed to preserve cognitive function during aging.


Share







Other News

Back to list